Tag Archives: Syndax Pharmaceuticals

May, 2018

31 May
Syndax and Nektar Therapeutics Partner for Immuno-Oncology Clinical Trial

WALTHAM, Mass. and SAN FRANCISCO, May 30, 2018 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, and Nektar Therapeutics (Nasdaq: NKTR) today announced a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar’s NKTR-214, a CD122-biased agonist, …
Share

11 January
Syndax and Genentech Collaborate to Evaluate Immunotherapy Combination in Metastatic Breast Cancer

WALTHAM, Mass., Jan. 10, 2018 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced a new clinical collaboration with Genentech, a member of the Roche Group. As part of the collaboration, the …
Share

4 January
Merck KGaA, Pfizer and Syndax Partner to Evaluate Cancer Combo in Ovarian Cancer

DARMSTADT, Germany & NEW YORK & WALTHAM, Mass.–(BUSINESS WIRE)–Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Pharmaceuticals, Inc. announced today that they have entered into a collaboration agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Syndax’s entinostat, an investigational oral small molecule that targets …
Share

31 March
Merck Teams Up with Syndax to Test Cancer Combination Regimen

Merck has teamed up with privately-held Syndax Pharmaceuticals to test combining Syndax’s investigational epigenetic therapy, entinostat, with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in cancer patients. The companies announced that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of this novel combination regimen in patients …
Share